ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer

Gao, Guanghui; Zhao, Jun; Ren, Shengxiang; Wang, Yina; Chen, Gongyan; Chen, Jianhua; Gu, Kangsheng; Guo, Renhua; Pan, Yueyin; Wang, Quanren; Li, Weixia; Yang, Xinfeng; Zhou, Caicun*安徽医科大学; 哈尔滨医科大学; 浙江大学; 同济大学; 1
Annals of Translational Medicine2022-4DOI: 10.21037/atm-21-4792
11被引19阅读
引用收藏
分享

摘要

Background: Limited data are available for the combination regimen of anti-programmed cell death protein 1 (PD-1) inhibitor and anti-angiogenic agents as second-line therapy for the treatment of patients with advanced non- small cell lung cancer (NSCLC), especially in patients with squamous NSCLC. This study assessed the efficacy and safety of camrelizumab plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) as second-line treatment in patients with advanced squamous NSCLC. @@@ Methods: In the Cohort 3 from a phase II dose-expansion trial, patients with advanced non-central squamous NSCLC who were immunotherapy naive and had failed prior first-line platinum- based chemotherapy received 200 mg of camrelizumab intravenously every 2 weeks plus oral apatinib at the recommended dose of 250 mg once daily. The primary endpoint was objective response rate (ORR) assessed by the investigators as per the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. @@@ Results: Cohort 3 was prematurely terminated because of slow accrual after 25 patients with advanced squamous NSCLC had been enrolled between 10 October 2018, and 3 March 2019. At the data cutoff date of 12 June 2020, the median follow-up was 13.3 (range, 1.6 to 19.2) months. Among all 25 participants, the ORR was 32.0% (95% CI: 14.9% to 53.5%), the clinical benefit rate was 44.0% (95% CI: 24.4% to 65.1%), and the disease control rate (DCR) was 84.0% (95% CI: 63.9% to 95.5%). Median progression-free survival (PFS) was 6.0 (95% CI: 3.5 to 8.1) months, and median overall survival (OS) was 13.3 (95% CI: 6.4 to 18.8) months. Furthermore, clinical benefits from this combination regimen were evident across all tumor PD ligand 1 (PD-L1) expression subgroups. The most common treatment-related adverse events (TRAEs) of grade 3 or higher were hypertension (44.0%) and palmar-plantar erythrodysesthesia (16.0%). As reported by the investigators, 3 participants (12.0%) died due to TRAEs (interstitial pneumonia, hemorrhage, and unknown reason; n=1 each, 4%). @@@ Conclusions: Camrelizumab plus apatinib as second-line therapy showed satisfactory antitumor activity in patients with non-central squamous NSCLC, regardless of tumor PD-L1 expression. Camrelizumab plus apatinib had a manageable safety profile in this patient population, and the toxic reactions observed were generally consistent with those in previously reported studies. Interstitial pneumonia and hemorrhage are important risks requiring careful monitoring and prompt intervention.

学科与关键词

关键词
Squamous non-small cell lung cancer (NSCLC)camrelizumabapatinibprogrammed cell death ligand 1 (PD-L1) expressionimmunotherapy
相关
加载中…
  • Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
    Gao, Guanghui; Ni, Jian; Wang, Yina; Ren, Shengxiang; Liu, Zhihua; Chen, Gongyan; Gu, Kangsheng; Zang, Aimin; Zhao, Jun; Guo, Renhua; He, Jianxing; Lin, Xiaoyan; Pan, Yueyin; Ma, Zhiyong; Wang, Zhehai; Fan, Min; Liu, Yunpeng; Cang, Shundong; Yang, Xinfeng; Li, Weixia; Wang, Quanren; Zhou, Caicun*Translational Lung Cancer Research, 2022, 11(6): 964-+.被引 10
  • Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi; Zhang, Wei-Jing; You, Rui; Zou, Xiong; Wang, Zhi-Qiang; Ouyang, Yan-Feng; Peng, Lan; Liu, You-Ping; Duan, Chong-Yang; Yang, Qi; Lin, Chao; Xie, Yu-Long; Chen, Si-Yuan; Liu, Yong-Long; Gu, Chen-Mei; Xie, Ruo-Qi; Huang, Pei-Yu; Hong, Ming-Huang; Hua, Yi-Jun; Chen, Ming-YuanJournal of Clinical Oncology, 2023, 41(14): 2571-+.被引 15
  • First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
    Ren, Shengxiang; Wang, Xicheng; Han, Bao-Hui; Pan, Yueyin; Zhao, Jun; Cheng, Yufeng; Hu, Sheng; Liu, Tianshu; Li, Yalun; Cheng, Ying; Feng, Jifeng; Yi, Shanyong; Gu, Shanzhi; Gao, Shegan; Luo, Yongzhong; Liu, Ying; Liu, Caigang; Duan, Huijie; Wang, Shuni; Yang, Xinfeng; Fan, Jia*; Zhou, Caicun*Journal for ImmunoTherapy of Cancer, 2024, 12(2): e007227.
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Translational Medicine
发表日期
2022-04
卷期
第 10 卷, 第 8 期
页码
441
DOI
10.21037/atm-21-4792
期刊等级
4区
成果收录
SCIE
资助标注
Jiangsu Hengrui Pharmaceuticals Co., Ltd.

作者

  • G

    Gao, Guanghui (第一作者)

    shanghai pulm hosp · tongji univ

  • Z

    Zhao, Jun

查看全部 13 位作者收起作者
  • R

    Ren, Shengxiang

    shanghai pulm hosp · tongji univ

  • W

    Wang, Yina

    1 · zhejiang univ

  • C

    Chen, Gongyan

    harbin med univ

  • C

    Chen, Jianhua

    hunan canc hosp

  • G

    Gu, Kangsheng

    1 · anhui med univ

  • G

    Guo, Renhua

  • P

    Pan, Yueyin

    anhui prov hosp · ustc

  • W

    Wang, Quanren

  • L

    Li, Weixia

  • Y

    Yang, Xinfeng

  • Z

    Zhou, Caicun (通讯)

    shanghai pulm hosp · tongji univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417